ArticleResearch square2026
Development of a STEAP1-Targeted Prostate Cancer Specific Antibody Drug Conjugate Platform with Immunostimulatory Properties.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Background: Patients with prostate cancer who develop androgen pathway modulation resistant (APMR) disease face lethal outcomes despite advances in androgen receptor-pathway inhibitors, chemotherapy, and PSMA-directed radioligands. Antibody-drug conjugates (ADCs) have demonstrated transformative efficacy in multiple malignancies, yet ADCs evaluated in patients with metastatic APMR have largely focused on direct tumor cytotoxicity without assessing immune mechanisms that may underpin durable therapeutic responses. Whether immune activation contributes to ADC efficacy in prostate cancer remains unexplored. Methods: We applied immune-centric design principles to ADC development targeting six transmembrane epithelial antigen of the prostate 1 (STEAP1), a prostate-lineage restricted, androgen receptor-regulated surface antigen. vandortuzumab-based ADCs were generated using multiple clinically validated linker-payload platforms. Constructs were evaluated using in vitro assays of Fcγ receptor engagement, antigen presentation, and T-cell activation, followed by in vivo testing in bone-metastatic and syngeneic immunocompetent APMR models. Results: STEAP1 specific Fcγ receptor engagement was required for optimal antigen presentation and downstream T-cell activation. Among tested payloads, exatecan-based ADCs demonstrated the strongest immunostimulatory activity. In bone-metastatic and immunocompetent APMR models, vandortuzumab-exatecan mediated durable tumor control and induced adaptive immune memory capable of preventing tumor rechallenge. Conclusions: These findings identify immune activation as an important determinant of ADC efficacy in APMR and demonstrate that vandortuzumab-exatecan functions as an immune-engaging ADC capable of inducing durable anti-tumor responses. Incorporating immune activation into ADC design may improve the therapeutic potential of ADCs for patients with advanced prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.